Definition and epidemiology
Complete androgen insensitivity syndrome (CAIS) is the most severe form of androgen insensitivity syndrome, a disorder of sex development (DSD) caused by complete loss of function of the androgen receptor (AR). Despite a 46,XY karyotype and testes that produce normal or supranormal testosterone, end organs are completely unresponsive to androgens, resulting in a typical female external phenotype at birth.
- Estimated prevalence is roughly 1 in 20,000 to 1 in 99,000 individuals with a 46,XY karyotype (exact figures vary by registry and ascertainment method).
- It accounts for a meaningful minority of girls presenting with bilateral inguinal hernias and for a subset of primary amenorrhea cases.
- Inheritance is X-linked recessive (AR gene on Xq11-12), so there is often a family history of maternal aunts or cousins with a similar presentation, though de novo mutations also occur.
- CAIS = 46,XY karyotype + female external phenotype + absent uterus.
- Caused by loss-of-function mutations in the androgen receptor gene (X-linked recessive).
- AMH is normal/intact, so Müllerian structures regress — explains the absent uterus.
- Testosterone and LH are normal to elevated (male range), unlike gonadal dysgenesis.
- Classic clinical clue: normal breast development but sparse/absent pubic and axillary hair.
- Common presentations: primary amenorrhea or inguinal hernia containing a gonad in a phenotypic female.
- Differentiate from MRKH (46,XX, normal hair/testosterone) and Swyer syndrome (46,XY, low testosterone, uterus present).
- Gonadectomy timing is debated; many guidelines favor post-pubertal removal due to malignancy risk balanced against endogenous estrogen production.
Etiology and risk factors
CAIS results from loss-of-function mutations in the AR gene, which encodes the androgen receptor. Hundreds of different mutations have been described, including point mutations, frameshift mutations, and premature stop codons, most of which impair hormone binding or DNA binding of the receptor.
- X-linked recessive inheritance: a 46,XY child of a carrier mother has a 50% chance of being affected.
- Carrier mothers are phenotypically normal females; family history on the maternal side (aunts, cousins) with primary amenorrhea or infertility is a classic clue.
- Up to one-third of cases arise from de novo mutations with no family history.
- Testes are present (often intra-abdominal, inguinal, or labial) and secrete normal or elevated testosterone and anti-Müllerian hormone (AMH), but target tissues cannot respond to androgens.
Pathophysiology
In normal male sexual differentiation, the SRY gene triggers testicular development; Sertoli cells secrete AMH causing Müllerian duct regression, and Leydig cells secrete testosterone, which is converted locally to dihydrotestosterone (DHT) to virilize external genitalia. In CAIS, the AR is nonfunctional, so neither testosterone nor DHT can act on target tissues.
- AMH secretion is intact and normal, so the Müllerian structures (uterus, fallopian tubes, upper vagina) regress as expected — this is why CAIS patients have no uterus.
- Because androgen signaling fails, the external genitalia develop along the default female pathway, producing normal-appearing female external genitalia, labia, and a short, blind-ending vagina (derived from the urogenital sinus).
- Testes remain undescended or partially descended (abdominal, inguinal, or labial) because testicular descent partly depends on androgen action.
- At puberty, testosterone is aromatized peripherally to estrogen, driving normal female breast development, but pubic and axillary hair is sparse or absent because hair growth in these regions is androgen dependent.
Clinical features
Presentation differs by age.
Infancy/childhood
- Bilateral or unilateral inguinal hernia containing a gonad (testis) in a phenotypically normal female infant — one of the most common presenting signs.
- External genitalia appear unambiguously female at birth; no genital ambiguity is typically noted.
Adolescence
- Primary amenorrhea with otherwise normal, often well-developed, breast development (estrogen from aromatization of testosterone).
- Normal female body habitus and height tracking toward tall-normal (influenced by Y chromosome growth genes).
- Sparse or absent pubic and axillary hair (classic distinguishing feature from other causes of primary amenorrhea).
- Short, blind-ending vagina on exam; absent cervix and uterus.
- Normal psychosocial female gender identity in the vast majority of patients.
Diagnosis
Diagnosis integrates clinical findings, karyotype, hormone levels, and sometimes genetic testing.
- Karyotype: 46,XY.
- Pelvic imaging (ultrasound or MRI): absent uterus and cervix, blind-ending vagina, gonads that may be intra-abdominal, inguinal, or labial.
- Hormone profile: testosterone normal-to-elevated for a male range (clue that this is not simple gonadal dysgenesis), LH elevated or normal, FSH normal, AMH normal/elevated reflecting functioning testicular tissue.
- Genetic testing: AR gene sequencing confirms a loss-of-function mutation and is useful for family counseling.
- Puberty: normal breast development with absent/sparse pubic and axillary hair, in the setting of primary amenorrhea, is a strong clinical pointer.
| Feature | CAIS |
|---|---|
| Karyotype | 46,XY |
| Uterus | Absent |
| Testosterone | Normal to high (male range) |
| Pubic/axillary hair | Sparse to absent |
| Breast development | Normal (estrogen from aromatization) |
Differential diagnosis
- Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome: 46,XX, absent uterus, but normal pubic/axillary hair and normal female-range testosterone (Müllerian agenesis with normal ovarian androgen production).
- Partial androgen insensitivity syndrome (PAIS): 46,XY with some residual AR function, producing ambiguous genitalia rather than a fully female phenotype.
- 5-alpha-reductase deficiency: 46,XY, ambiguous or male-appearing genitalia at birth that often virilize at puberty (DHT-independent AR still functions), unlike CAIS.
- Swyer syndrome (46,XY complete gonadal dysgenesis): 46,XY, female phenotype, but streak gonads with low testosterone/estrogen and absent spontaneous puberty (no breast development without hormone therapy), and uterus is present.
- Congenital adenomatous or other causes of primary amenorrhea: distinguished by karyotype and hormone panel.
Management
Management is multidisciplinary, involving endocrinology, gynecology, urology, genetics, and psychological support, and should emphasize shared decision-making with the patient (and family, when the patient is a minor).
- Gonadectomy timing is debated. Testes in CAIS carry a low but real risk of germ cell malignancy (historically cited around 2 to 5% by adulthood, lower than in other DSDs with dysgenetic gonads). Many current guidelines favor delaying gonadectomy until after puberty is complete, since the intact testes provide endogenous estrogen (via peripheral aromatization) for pubertal development and bone health, with gonadectomy performed after puberty followed by estrogen replacement. Some centers still recommend earlier removal; practice varies internationally, so this should be individualized and discussed with the patient.
- Estrogen replacement therapy is indicated after gonadectomy (or if endogenous production is insufficient) to maintain secondary sexual characteristics and bone density.
- Vaginal dilation therapy (and rarely vaginoplasty) may be offered for sexual function if the vagina is short, typically initiated when the patient is ready, often in later adolescence or adulthood.
- Psychological support and peer support groups are an important part of long-term care given the complex diagnosis and its implications for identity and fertility.
- Fertility: patients are infertile (absent uterus/ovaries); fertility preservation options are limited, though family-building discussions (e.g., adoption, surrogacy with donor gametes) can be part of counseling.
- Genetic counseling for the family given X-linked recessive inheritance.
Complications and prognosis
- Gonadal germ cell tumors (gonadoblastoma, seminoma): low but increased lifetime risk compared with the general population, driving the gonadectomy timing discussion.
- Infertility: universal, due to absent uterus and ovaries.
- Osteoporosis/osteopenia risk: can occur if estrogen replacement is inadequate after gonadectomy or if there is a delay in diagnosis/treatment.
- Psychosocial impact: the diagnosis, karyotype, and infertility can be distressing; sensitive, staged disclosure and psychological support improve long-term coping.
- Overall prognosis for general health and life expectancy is excellent; most individuals live as healthy women with normal life expectancy once appropriately managed.
Think "CAIS = Can't Act, Internally Smooth": the receptor Can't Act on androgens, so externally female but Internally no uterus (Smooth = AMH still works, Müllerian ducts regress).
Practice questions
1. A 16-year-old presents with primary amenorrhea. She has normal breast development (Tanner V) but absent pubic and axillary hair. Pelvic ultrasound shows no uterus and a blind-ending vaginal pouch. Serum testosterone is elevated for a female reference range, and karyotype shows 46,XY. Which of the following is the most likely diagnosis?
2. A 2-year-old phenotypic female is brought in for repair of a right inguinal hernia. During surgery, a gonad resembling a testis is found within the hernia sac. Karyotype analysis is subsequently obtained. Which karyotype and hormonal profile would most strongly support a diagnosis of complete androgen insensitivity syndrome?
3. A clinician is counseling a 17-year-old with confirmed CAIS and her family about management of her intra-abdominal gonads. Which of the following best reflects current practice considerations regarding gonadectomy timing in CAIS?
Frequently asked questions
What causes complete androgen insensitivity syndrome?
CAIS is caused by loss-of-function mutations in the androgen receptor gene on the X chromosome, inherited in an X-linked recessive pattern. In 46,XY individuals, testes produce normal or elevated testosterone, but because the androgen receptor cannot respond, tissues fail to masculinize, resulting in a female external phenotype despite a male chromosomal pattern.
What are the first signs of CAIS?
In infancy, the first sign is often a bilateral or unilateral inguinal hernia containing a testis in a baby who otherwise looks like a typical female. In adolescence, the first sign is usually primary amenorrhea despite normal breast development, often with little or no pubic and axillary hair.
How is CAIS diagnosed?
Diagnosis combines a 46,XY karyotype, pelvic imaging showing an absent uterus with a blind-ending vagina, hormone testing showing normal-to-high testosterone and LH, and often genetic sequencing confirming an androgen receptor gene mutation. The combination of female phenotype with male-range testosterone and no uterus is the key diagnostic pattern.
Is complete androgen insensitivity syndrome curable?
CAIS is not curable because it is a genetic condition affecting receptor function, but it is very manageable. Treatment focuses on gonadectomy timing decisions, estrogen replacement to maintain bone health and secondary sexual characteristics, and psychological support, allowing most patients to live healthy lives, though infertility is permanent.
CAIS vs Swyer syndrome — what is the difference?
Both involve a 46,XY karyotype with a female phenotype, but CAIS has functioning testes producing normal-to-high testosterone with intact AMH action (so no uterus), while Swyer syndrome involves streak (nonfunctional) gonads with low testosterone and low AMH, so a uterus is actually present and spontaneous puberty does not occur without hormone therapy.
Can someone with CAIS get pregnant?
No, individuals with CAIS cannot become pregnant because they lack a uterus and ovaries, which are necessary for pregnancy. Family-building options such as adoption or surrogacy using donor eggs may be discussed as part of long-term counseling.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: E34.1
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.